ClouDr Group’s Revenue Halves in 2025 as Losses Deepen and Dividend Scrapped

An update from ClouDr Group Limited ( (HK:9955) ) is now available.

ClouDr Group Limited reported a sharp deterioration in its 2025 financial performance, with revenue halving to RMB1.62 billion from RMB3.49 billion and gross profit falling 10%, reflecting steep declines across both in-hospital and out-of-hospital solutions. The company’s operating loss more than doubled and its net loss nearly doubled year on year, while adjusted net loss also widened, highlighting pressure on underlying operations despite non-IFRS adjustments.

Within its product mix, in-hospital solutions revenue dropped almost 56% and out-of-hospital solutions fell 46%, as value-added services contracted heavily, partially offset by strong growth in P2M solutions, especially out-of-hospital, where sales rose nearly 148%. The board decided not to recommend a final dividend for 2025, signaling a focus on preserving cash and navigating heightened operational and policy risks that have led to impairments and special provisions, which may weigh on investor sentiment and capital allocation plans.

The most recent analyst rating on (HK:9955) stock is a Sell with a HK$0.86 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.

More about ClouDr Group Limited

ClouDr Group Limited is a healthcare technology company listed in Hong Kong that provides in-hospital and out-of-hospital digital solutions to medical institutions and pharmaceutical partners. Its offerings include subscription-based targeted marketing, value-added services, and P2M solutions focused on distributing proprietary and strategically partnered pharmaceutical products in the Chinese healthcare market.

Average Trading Volume: 893,964

Technical Sentiment Signal: Sell

Current Market Cap: HK$418.2M

For detailed information about 9955 stock, go to TipRanks’ Stock Analysis page.